WBR0536: Difference between revisions

Jump to navigation Jump to search
Rim Halaby (talk | contribs)
Created page with "{{WBRQuestion |QuestionAuthor={{Rim}} |ExamType=USMLE Step 1 |MainCategory=Pharmacology |SubCategory=Neurology |MainCategory=Pharmacology |SubCategory=Neurology |MainCategory=..."
 
No edit summary
Line 1: Line 1:
{{WBRQuestion
{{WBRQuestion
|QuestionAuthor={{Rim}}
|QuestionAuthor={{Rim}} {{Alison}}
|ExamType=USMLE Step 1
|ExamType=USMLE Step 1
|MainCategory=Pharmacology
|MainCategory=Pharmacology
Line 20: Line 20:
|MainCategory=Pharmacology
|MainCategory=Pharmacology
|SubCategory=Neurology
|SubCategory=Neurology
|Prompt=A 10 year old boy is brought by his mother to the physician's office for recurrent abrupt transient loss of consciousness and a blank stare.  Following appropriate work-up, the patient is diagnosed with absence seizure.  The patient is started on a new medication to treat his condition.  Which of the following best describes the mechanism of action of the prescribed medication?
|Prompt=A 10-year-old male is brought to the physician's office by his mother for a recurrent, abrupt transient loss of consciousness and blank stare.  Upon appropriate work-up, the patient is diagnosed with absence seizure and is administered a medication to treat his condition.  Which of the following mechanisms of action best correlates to the prescribed medication?
|Explanation=Ethosuximide is a succinimide antiepileptic drug that is considered the first line treatment for absence seizure (petit mal). It is a low voltage-activated thalamic T-type calcium channel blocker.   
|Explanation=[[Ethosuximide]], a succinimide antiepileptic drug, is the first line treatment for absence seizure (petit mal). It is a low voltage-activated thalamic T-type calcium channel blocker.   


Ethosuximide has a relatively safe side effect profile with a rare frequency of adverse drug reactions.  Most common side effects include GI distress, fatigue and headache.  A less common, but more severe side effect is Stevens-Johnson syndrome, a dermatologic disorder characterized by fever, bullous formation, and necrosis with skin sloughing.
Ethosuximide has a rare frequency of adverse drug reactions.  Most common side effects include GI distress, fatigue, and headache.  A less common, but more severe side effect is Stevens-Johnson syndrome, a dermatologic disorder characterized by fever, bullous formation, and necrosis with skin sloughing.


In addition to ethosuximide, valproic acid can often be used to treat absence seizures as well.
In addition, valproic acid can often be used to treat absence seizures as well.
 
|EducationalObjectives= [[Ethosuxamide]], the first line treatment for absence seizures, is a thalamic T-type calcium channel blocker.
|References= First Aid 2014 page 485


Educational Objective: Ethosuxamide is the first line treatment for absence seizures.  It is a thalamic T-type calcium channel blocker.
|AnswerA=Inactivation of dopamine receptors
|AnswerA=Inactivation of dopamine receptors
|AnswerAExp=Antipsychotics are used to treat psychiatric diseases, such as schizophrenia, act by inactivation of dopamine receptors.
|AnswerAExp=Antipsychotics are used to treat psychiatric diseases, such as schizophrenia, act by inactivation of dopamine receptors.
|AnswerB=Inactivation of sodium channels but not effect on GABA  
|AnswerB=Inactivation of sodium channels but not effect on GABA  
|AnswerBExp=Phenytoin is not commonly used for absence seizures.  It is used, however, in tonic-clonic generalized seizure and partial seizures. Its mechanism of action is inactivation of sodium channels.  
|AnswerBExp=Phenytoin's mechanism of action is the inactivation of sodium channels. Although Phenytoin is not commonly administered to treat absence seizures, it is used in tonic-clonic generalized seizure and partial seizures.
 
Also, carbamazepine is not first line treatment for absence seizures.  It is a first line treatment for partial seizures and tonic-clonic generalized seizures.  Similar to phenytoin, carbamazepine acts by inactivation of sodium channels.
|AnswerC=Concomitant inactivation of sodium channels and activation of GABA
|AnswerC=Concomitant inactivation of sodium channels and activation of GABA
|AnswerCExp=Topiramate blocks sodium channels and increases the action of GABA. It is not commonly used in absence seizures.  It is effective in partial and tonic-clonic generalized seizures.
|AnswerCExp=Topiramate blocks sodium channels and increases the action of GABA. It is not commonly administered to treat absence seizures, but is effective in treating partial and tonic-clonic generalized seizures.
 
|AnswerD=Inactivation of thalamic T-type calcium channels
|AnswerD=Inactivation of thalamic T-type calcium channels
|AnswerDExp=Ethosuximide is considered first line treatment for absence seizures.  It blocks thalamic T-type calcium channels.
|AnswerDExp=See overall explanation.
|AnswerE=Inhibition of GABA reuptake
|AnswerE=Inhibition of GABA reuptake
|AnswerEExp=Tiagabine is effective in partial seizures.  It acts by inhibition of GABA reuptake.  It is not usually used to treat absence seizures.
|AnswerEExp=Tiagabine, which acts by inhibition of GABA reuptake, is effective in partial seizures, but is not usually used to treat absence seizures.
|RightAnswer=D
|RightAnswer=D
|WBRKeyword=absence, seizure, seizures, petit, mal, petit mal, ethosuximide, calcium, channel, blocker, t-type, t type, thalamic, mechanism, action
|WBRKeyword=absence seizure, seizures, petit mal, ethosuximide, calcium channel blocker, t-type, mechanism of action, neurological,
|Approved=No
|Approved=Yes
}}
}}

Revision as of 18:06, 30 July 2014

 
Author [[PageAuthor::Rim Halaby, M.D. [1] (Reviewed by Alison Leibowitz)]]
Exam Type ExamType::USMLE Step 1
Main Category MainCategory::Pharmacology
Sub Category SubCategory::Neurology
Prompt [[Prompt::A 10-year-old male is brought to the physician's office by his mother for a recurrent, abrupt transient loss of consciousness and blank stare. Upon appropriate work-up, the patient is diagnosed with absence seizure and is administered a medication to treat his condition. Which of the following mechanisms of action best correlates to the prescribed medication?]]
Answer A AnswerA::Inactivation of dopamine receptors
Answer A Explanation AnswerAExp::Antipsychotics are used to treat psychiatric diseases, such as schizophrenia, act by inactivation of dopamine receptors.
Answer B AnswerB::Inactivation of sodium channels but not effect on GABA
Answer B Explanation AnswerBExp::Phenytoin's mechanism of action is the inactivation of sodium channels. Although Phenytoin is not commonly administered to treat absence seizures, it is used in tonic-clonic generalized seizure and partial seizures.
Answer C AnswerC::Concomitant inactivation of sodium channels and activation of GABA
Answer C Explanation AnswerCExp::Topiramate blocks sodium channels and increases the action of GABA. It is not commonly administered to treat absence seizures, but is effective in treating partial and tonic-clonic generalized seizures.
Answer D AnswerD::Inactivation of thalamic T-type calcium channels
Answer D Explanation AnswerDExp::See overall explanation.
Answer E AnswerE::Inhibition of GABA reuptake
Answer E Explanation AnswerEExp::Tiagabine, which acts by inhibition of GABA reuptake, is effective in partial seizures, but is not usually used to treat absence seizures.
Right Answer RightAnswer::D
Explanation [[Explanation::Ethosuximide, a succinimide antiepileptic drug, is the first line treatment for absence seizure (petit mal). It is a low voltage-activated thalamic T-type calcium channel blocker.

Ethosuximide has a rare frequency of adverse drug reactions. Most common side effects include GI distress, fatigue, and headache. A less common, but more severe side effect is Stevens-Johnson syndrome, a dermatologic disorder characterized by fever, bullous formation, and necrosis with skin sloughing.

In addition, valproic acid can often be used to treat absence seizures as well.
Educational Objective: Ethosuxamide, the first line treatment for absence seizures, is a thalamic T-type calcium channel blocker.
References: First Aid 2014 page 485]]

Approved Approved::Yes
Keyword WBRKeyword::absence seizure, WBRKeyword::seizures, WBRKeyword::petit mal, WBRKeyword::ethosuximide, WBRKeyword::calcium channel blocker, WBRKeyword::t-type, WBRKeyword::mechanism of action, WBRKeyword::neurological
Linked Question Linked::
Order in Linked Questions LinkedOrder::